Correspondence 0000950170-23-069895 from Virax Biolabs Group Ltd (VRAX) (CIK 0001885827) (VRAX)
Virax Biolabs Group Ltd (VRAX) (CIK 0001885827)
Date: Dec. 13, 2023 · CIK: 0001885827 · Accession: 0000950170-23-069895
AI Filing Summary & Sentiment
File numbers found in text: 333-275893
Letter
Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
December 13, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn:Cindy Polynice
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-3
Filed December 5, 2023
File No. 333-275893
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 15, 2023, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
December 13, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn:Cindy Polynice
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-3
Filed December 5, 2023
File No. 333-275893
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 15, 2023, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
James Foster
Chief Executive Officer
DOCPROPERTY "DocID" \* MERGEFORMAT 23722827.1
240437-10005